Aldevron News: Vaccines

In the News: Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline

Moderna, Inc. (Nasdaq:MRNA), and Aldevron have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline. Specifically, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna’s pipeline.

Read More

Aldevron Honored at 2021 State of the State Address for its 40+ COVID-19 Programs

The Joint Session of the State of North Dakota’s 67th Legislative Assembly held its opening sessions earlier this week, and featured Governor Doug Burgum’s 2021 State of the State address. Burgum reflected on the progress and challenges of the past year, calling for bold action and investments in infrastructure and other priorities to position the state for a bright future.

Read More

In the News: Pharma's Almanac - The Pivotal Role of Plasmid DNA

Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.

Read More

Aldevron's Plasmids Used In Cancer Prevention Vaccine Trial

Aldevron client and partner, Calviri, testing vaccine to prevent cancer in trial using 800 dogs

Aldevron has the privilege of working with thousands of clients trying to solve the world’s biggest health challenges and cancer is at the top of the list. Finding a preventative therapy has long been the goal. Our partner, Calviri, is testing a vaccine in a canine trial that could lead to a treatment for humans.

Read More

Aldevron Manufactures Malaria DNA Vaccine for Naval Medical Research Center

Today, at the State of Technology Conference with Senator Hoeven and the Fargo Moorhead West Fargo Chamber of Commerce, Aldevron announces completing the production of a DNA-based vaccine to combat malaria under a contract with the Naval Medical Research Center (NMRC).  Aldevron, a leading contract manufacturer of plasmid DNA, proteins, and antibodies, produced three plasmid DNA constructs that have been delivered to NMRC in preparation for a phase I/II challenge study.

Read More